Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 27

recruiting
3 973
countries
28
conditions
2 104

1 112 trials match your criteria

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Hypoxia+2

Recruiting

Oxygen Therapy to Prevent Breathing Problems After Non-Cardiac Surgery in Patients at Risk for Postoperative Complications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Oxygen

Acute myeloid leukaemia+3

Recruiting

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine

Chronic graft versus host disease

Recruiting

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib

Bladder cancer

Recruiting

Study on the Effectiveness of Gemcitabine Hydrochloride for Patients with Low Grade Bladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine Hydrochloride

Acute lymphocytic leukaemia+4

Recruiting

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib

Malabsorption

Recruiting

Study on the Safety of ELGN-2112 for Preterm Infants with Intestinal Malabsorption

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Insulin Human

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Pancreatic failure

Recruiting

Study on Pancreatic Enzyme Replacement Therapy for Adults with Pancreatic Exocrine Insufficiency After Pancreatic Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pancreas Powder

Indolent systemic mastocytosis

Recruiting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.